Onco-Genomas Brasil: Mapping Breast and Prostate Cancer in the Brazilian Public Health Sys
This project aims to perform complete sequencing of the somatic (tumor) and germline exomes during clinical investigation of cancer patients treated through the Brazilian Unified Health System to generate genomic and phenotypic data for the Brazilian Ministry of Health's National Precision Genomics and Health Program,
| Condition(s) | Breast Cancer, Prostate Cancer |
|---|---|
| Status | Recruiting |
| Study type | Observational |
| Summary | This project aims to perform complete sequencing of the somatic (tumor) and germline exomes during clinical investigation of cancer patients treated through the Brazilian Unified Health System to generate genomic and phenotypic data for the Brazilian Ministry of Health's National Precision Genomics and Health Program, called Genomas Brasil, as well as to collect data on the population's ancestry. |
| Who can participate | Inclusion criteria for breast cancer patients (Arm 1): * Women aged ≥ 18 years; * Brazilian nationality; * After review at the Hospital Moinhos de Vento, confirmed histological diagnosis of breast carcinoma with overexpression of HER2 (classified by immunohistochemistry as 3+ or 2+ with positive in-situ hybridization) or triple-negative (estrogen and progesterone receptors \<1% and no overexpression of HER2); * Clinical stage II or III for HER2-positive and I, II and III for triple-negative patients - American Joint Committee on Cancer (AJCC) 8th edition; * HER2- positive patients: must undergo neoadjuvant chemotherapy plus trastuzumab in the following regimens: anthracycline (doxorubicin or epirubicin) followed by taxane (docetaxel or paclitaxel), combined with trastuzumab, or a non-anthr |
| Ages | 18 Years |
| Sex | All |
| Lead sponsor | Hospital Moinhos de Vento |
| Locations | Manaus, Amazonas, Brazil; Manaus, Amazonas, Brazil; Vitória, Espírito Santo, Brazil; Itabuna, Estado de Bahia, Brazil; Vitória da Conquista, Estado de Bahia, Brazil; Brasília, Federal District, Brazil (+19 more sites) |
| Start date | 2022-11-09 |
| NCT ID | NCT05306600 |
| Official listing | https://clinicaltrials.gov/study/NCT05306600 |